Big Pharma
27 October 2025 As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.
23 October 2025
22 October 2025
21 October 2025
21 October 2025
20 October 2025
Latest Features
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
More News
16 October 2025 After saving hundreds of thousands of dollars ‘with my laptop and ChatGPT’, the biotech’s trademarks leader says lawyers need to discover how the tech can reduce external spend.
13 October 2025 A recent survey shows heavy opposition to the proposal which could leave university licensing struggling, chill investment in startups, and threaten technology transfers.
10 October 2025 A new report highlights widespread mental health issues among legal professionals, leading to poor wellbeing and career disillusionment.
9 October 2025 The pharma giant extends market exclusivity for a top-selling drug accounting for nearly half of its multi-billion-dollar sales.
9 October 2025 The promises and pitfalls of AI took centre stage at CIPA’s annual congress in Bristol this week, as Sarah Speight reports.
8 October 2025 A 2021 Supreme Court ruling changed how patent terms are calculated, forcing pharma companies to rethink their IP strategies. Juliana Neves of Licks explains the key changes, upcoming reforms, and how companies can protect their portfolios effectively.
7 October 2025 The pharma giant will share rights to new innovations with an AI-driven organoid platform designed to produce fully human antibodies in weeks.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox